Works matching IS 10685308 AND DT 2021 AND VI 32 AND IP 11

Results: 10

Your Medication Information.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 9, doi. 10.1002/pu.30800
Publication type:
Article
Fluoxetine's effect on depression following stroke not significant.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 8, doi. 10.1002/pu.30799
Publication type:
Article
Dose tapering in opioid treatment increases risk of overdose.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 8, doi. 10.1002/pu.30798
Publication type:
Article
High‐dose buprenorphine induction in emergency care appears safe.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 8, doi. 10.1002/pu.30797
Publication type:
Article
Aducanumab: Boon or bust?
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 7, doi. 10.1002/pu.30796
Publication type:
Article
Some genetic factors linked to risk of ADHD treatment discontinuation.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 4, doi. 10.1002/pu.30795
Publication type:
Article
Some antipsychotics, mainly injectables, increase likelihood of continuous treatment.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 3, doi. 10.1002/pu.30794
Publication type:
Article
Potentially inappropriate medications in the elderly.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 2, doi. 10.1002/pu.30793
Publication type:
Article
Longer course of esketamine nasal spray benefits initial treatment nonresponders.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 1, doi. 10.1002/pu.30792
Publication type:
Article
Discontinuing pimavanserin carries risk in treating dementia‐related psychosis.
Published in:
Brown University Psychopharmacology Update, 2021, v. 32, n. 11, p. 1, doi. 10.1002/pu.30791
Publication type:
Article